Literature DB >> 710970

Drug metabolism in hepatosplenic schistosomiasis in the Sudan: a study with antipyrine.

M Homeida, S Y Salih, R A Branch.   

Abstract

The disposition of antipyrine following oral administration of 1200 mg has been investigated in 10 patients with histologically confirmed hepatosplenic schistosomiasis and 11 normal subjects living in Sudan. Drug metabolising activity as assessed by antipyrine clearance was similar in patients when compared with normal controls. We conclude that antipyrine disposition is normal in patients with clinically compensated hepatosplenic schistosomiasis.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 710970      PMCID： PMC1412193          DOI： 10.1136/gut.19.9.808

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  12 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Effect of Schistosoma mansoni infection on the hepatic drug-metabolizing capacity of mice.

Authors:  Y N Cha; R Edwards
Journal:  J Pharmacol Exp Ther       Date:  1976-11       Impact factor: 4.030

3.  Infection with Schistosoma mansoni in the Gezire area of the Sudan.

Authors:  A H Omer; P J Hamilton; T F Marshall; C C Draper
Journal:  J Trop Med Hyg       Date:  1976-07

4.  Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration.

Authors:  P B Andreasen; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1974-12       Impact factor: 6.875

5.  Clearance of antipyrine-dependence of quantitative liver function.

Authors:  P B Andreasen; L Ranek; B E Statland; N Tygstrup
Journal:  Eur J Clin Invest       Date:  1974-04       Impact factor: 4.686

6.  A new active metabolite of "Miracil D".

Authors:  D Rosi; G Peruzzotti; E W Dennis; D A Berberian; H Freele; S Archer
Journal:  Nature       Date:  1965-12-04       Impact factor: 49.962

7.  Metabolism of niridazole in various species, including man.

Authors:  J W Faigle; H Keberle
Journal:  Ann N Y Acad Sci       Date:  1969-10-06       Impact factor: 5.691

8.  Mutagenic activities in vitro and in vivo of five antischistosomal compounds.

Authors:  R P Batzinger; E Bueding
Journal:  J Pharmacol Exp Ther       Date:  1977-01       Impact factor: 4.030

9.  Determinants of serum antipyrine half-lives in patients with liver disease.

Authors:  R A Branch; C M Herbert; A E Read
Journal:  Gut       Date:  1973-07       Impact factor: 23.059

10.  Clinical aspects of hepatosplenic schistosomiasis: a contrast with cirrhosis.

Authors:  G Rebouças
Journal:  Yale J Biol Med       Date:  1975-11
View more
  7 in total

Review 1.  Clinical pharmacokinetics of anthelmintic drugs.

Authors:  G Edwards; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

2.  Assessment of oxidative metabolism in adults with hepatocellular carcinoma in the Sudan.

Authors:  M M Homeida; T K Daneshmend; E M Ali; A G Yousif-Elkadaru; B M Arbab
Journal:  Gut       Date:  1986-04       Impact factor: 23.059

3.  Disposition of oral metronidazole in hepatic cirrhosis and in hepatosplenic schistosomiasis.

Authors:  T K Daneshmend; M Homeida; C M Kaye; A A Elamin; C J Roberts
Journal:  Gut       Date:  1982-10       Impact factor: 23.059

Review 4.  A review of the pharmacokinetic implications of schistosomiasis.

Authors:  Kyle J Wilby; Samuel E Gilchrist; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2013-08       Impact factor: 6.447

5.  Propranolol disposition in patients with hepatosplenic schistosomiasis.

Authors:  M M Homeida; H M Ali; B M Arbab; D W Harron
Journal:  Br J Clin Pharmacol       Date:  1987-09       Impact factor: 4.335

6.  The pharmacokinetics of antipyrine in patients with graded severity of schistosomiasis.

Authors:  I el-Raghy; D J Back; F Osman; M A Nafeh; M L Orme
Journal:  Br J Clin Pharmacol       Date:  1985-10       Impact factor: 4.335

7.  The hepatic and duodenal activities of some drug metabolizing enzymes in chickens: influence of infection with Escherichia coli endotoxin and coccidiosis.

Authors:  B H Ali
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Jul-Sep       Impact factor: 2.569
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.